SymBio Pharmaceuticals Limited (TYO:4582)

Japan flag Japan · Delayed Price · Currency is JPY
118.00
+3.00 (2.61%)
Mar 10, 2026, 11:05 AM JST
-31.40%
Market Cap 7.36B
Revenue (ttm) 1.31B
Net Income (ttm) -4.78B
Shares Out 63.99M
EPS (ttm) -95.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,492,200
Average Volume 17,946,415
Open 118.00
Previous Close 115.00
Day's Range 113.00 - 119.00
52-Week Range 81.00 - 229.00
Beta 0.46
RSI 46.98
Earnings Date May 7, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses. The company was incorporated in 2005 and is bas... [Read more]

Sector Healthcare
Founded 2005
Employees 108
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4582
Full Company Profile

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.67% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.

Financial Statements

News

There is no news available yet.